Biomarkers Market

Market Overview:

The global biomarkers market size reached US$ 68.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 139.8 Billion by 2028, exhibiting a growth rate (CAGR) of 11.5% during 2023-2028.

Biomarkers, also known as biological markers, are molecules or genes that are used as indicators of the health or status of an organ, tissue, or cell. In addition to blood and bodily fluids, biomarkers are also found in tissues. In the discovery and development of new drugs, biomarkers are used for risk assessment, molecular diagnostics, disease diagnosis, DNA fingerprinting, and eliminating complexity. As a result, they play a crucial role in improving the drug development process, drug validation and testing, sample preparation and assay development. Biomarkers are often integrated with key imaging technologies that can provide clear images of oncology tumors and other problems while also eliminating the possibility of radiation exposure during CT scans and MRI scans.

Biomarkers Market Trends:

The market is majorly driven by the rising incidences of numerous chronic diseases among the masses, particularly in the geriatric population. In addition to this, the increasing implementation of biomarkers in infectious disease diagnosis is propelling the market. Moreover, continual developments in biomarker-based diagnostics, such as biomarker signatures resulting in faster drug development, non-invasive testing, and early diagnosis, are also creating a positive market outlook. In line with this, the rapid utilization of biomarkers in the development of companion diagnostics to identify drug target molecules is providing an impetus to the market. Also, the escalating demand for personalized medicine, along with a paradigm shift toward biomarker studies from conventional pathophysiology and epidemiology methods, is fueling the market. Furthermore, a considerable rise in the number of contract research organizations facilitating cost-efficient clinical trials are creating a positive market outlook. Some of the other factors contributing to the market include extensive research and development (R&D) activities and the increasing medical expenditure.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global biomarkers market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, type, disease, application and end user.

Breakup by Product:

• Consumables
• Services
• Software
   

Breakup by Type:

• Efficacy Biomarkers
• Safety Biomarkers
• Validation Biomarkers
   

Breakup by Disease:

• Cancer
• Cardiovascular Disorders
• Neurological Disorders
• Immunological Disorders
• Renal Disorders
• Others
   

Breakup by Application:

• Diagnostics
• Drug Discovery and Development
• Personalized Medicine
• Others
   

Breakup by End User:

• Pharmaceutical and Biotechnology Companies
• Diagnostic and Research Laboratories
• Hospitals and Specialty Clinics
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Bio-Rad Laboratories Inc., Charles River Laboratories International Inc., Epigenomics AG, Eurofins Scientific SE, Merck KGaA, Perkinelmer Inc., Qiagen N.V, Quanterix Corporation, SphingoTec GmbH and Thermo Fisher Scientific Inc.

Report Coverage: